Lipase News and Research

RSS

Updated guidelines for management of acute pancreatitis

Updated guidelines on the management of acute pancreatitis, a condition that causes acute inflammation of the pancreas, appear in the September issue of The American Journal of Gastroenterology.

5 Sep 2013

Scientists discover bacterium that stores biodegradable plastic

In Bolivia, in the largest continuous salt desert in the world, researchers from the Polytechnic University of Catalonia have found a bacterium that stores large amounts of PHB, a prized polymer. This biodegradable plastic is used by the food and pharmaceutical industries, for example to produce nanospheres to transport antibiotics.

11 Jul 2013

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

ARIAD Pharmaceuticals, Inc. today announced that the European Commission has granted a marketing authorization for Iclusig (ponatinib) as an orphan medicinal product for two indications.

2 Jul 2013

Synageva BioPharma presents data on cholesteryl ester storage disease at NLA annual meeting

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, announced three poster presentations at the National Lipid Association annual meeting held in Las Vegas, Nevada, May 30- June 2, 2013, as well as a Synageva-sponsored satellite symposium held on Friday, May 31, 2013.

1 Jun 2013

CREON Delayed-Release Capsules now available in US for patients with EPI

AbbVie announced that a new, higher-dose capsule of CREON (pancrelipase) Delayed-Release Capsules is commercially available in the United States. The U.S. Food and Drug Administration recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.

31 May 2013

FDA designates Synageva's sebelipase alfa as Breakthrough Therapy for early onset LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset lysosomal acid lipase deficiency, also known as Wolman disease.

20 May 2013

Scientists reveal inside story of European regulatory review and approval of Glybera

The scientists who led the team that developed Glybera, the first gene therapy drug approved for use in the Western world, provide a fascinating first-person account of their pioneering work in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

16 May 2013

Synageva BioPharma reports study results of sebelipase alfa in adults with late onset LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today reported 12-month results from an ongoing extension study with sebelipase alfa in adults with late onset Lysosomal Acid Lipase Deficiency.

9 May 2013

Xenon Pharmaceuticalsn receives BIOTECanada's Gold Leaf Company of the Year Award for 2013

Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded BIOTECanada's Gold Leaf Company of the Year Award for 2013.

22 Apr 2013

Single gene therapy session can cure diabetes

Researchers from the Universitat Aut-noma de Barcelona (UAB), led by F-tima Bosch, have shown for the first time that it is possible to cure diabetes in large animals with a single session of gene therapy. As published this week in Diabetes, the principal journal for research on the disease, after a single gene therapy session, the dogs recover their health and no longer show symptoms of the disease.

10 Feb 2013

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Synageva BioPharma Corp. (Synageva), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology

5 Feb 2013

TRIP-Br2 plays a major role in energy metabolism and fat storage

As part of their ongoing research on the physiologic factors that contribute to the development of obesity, Joslin Diabetes Center scientists have identified a cell cycle transcriptional co-regulator - TRIP-Br2 - that plays a major role in energy metabolism and fat storage.

6 Jan 2013

Scientists discover new gene mechanism that appears to regulate triglyceride levels

Scientists at the Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA) at Tufts University have discovered a new gene mechanism that appears to regulate triglyceride levels.

15 Dec 2012

Ponatinib offers new hope in drug-resistant leukemia

An investigational tyrosine kinase inhibitor, ponatinib, has shown high levels of activity in patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

5 Dec 2012

Illuminate PatientView to be introduced at Radiological Society of North America meeting

Illuminate PatientView, the newest application of Softek Illuminate's search engine and data aggregation technology, will be introduced at the Radiological Society of North America's annual meeting Nov. 25-30 at Chicago's McCormick Place and demonstrated by Softek associates in booth 9141.

20 Nov 2012

Study identifies monoacylglycerol lipase as new therapeutic target to treat Alzheimer's

Research led by Chu Chen, PhD, Associate Professor of Neuroscience at LSU Health Sciences Center New Orleans, has identified an enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target to treat or prevent Alzheimer's disease.

2 Nov 2012

High-fat Western diet could lead to development of atherosclerosis

Columbia University Medical Center (CUMC) researchers have found that a diet high in saturated fat raises levels of endothelial lipase (EL), an enzyme associated with the development of atherosclerosis, and, conversely, that a diet high in omega-3 polyunsaturated fat lowers levels of this enzyme.

10 Oct 2012